CME Activities

Webcast Details

Return to Search

Chronic Lymphocytic Leukemia

All webcasts are free to view. You must only pay if you wish to access the post test following the webcast, in order to earn CME credit. You must be logged in to take the Post-Test.

11/08/2019 - 11/08/2022
Jennifer Woyach, MD, and Kerry A. Rogers, MD
Dr. Kerry Rogers      Dr. Jennifer Woyach

As a result of this educational activity, webcast participants will be able to: RECOGNIZE that CLL is a chronic lymphoid malignancy which does not need treatment at diagnosis if asymptomatic and has a survival of many years; RECOGNIZE that CLL patients are at higher risk for second cancers or infection so it is important so all CLL patients with CLL should get all age appropriate cancer screenings and vaccinations; UNDERSTAND indications for treatment in CLL and the rationale for the watch and wait approach; and UNDERSTAND some serious side effects that can occur with oral targeted therapies in CLL.

You’ll also learn about the following:

  • Risks for CLL
  • Current approach to treatment of CLL
  • Roles and limitations of automated WBC differentials
  • Initial approach to lymphocytosis
  • Emerging trends in first line treatment of CLL
  • Role of age of the patient in therapeutic decision making
  • Stem cell transplants

Today on MedNet21, we're going to discuss Chronic Lymphocytic Leukemia.

Learners should expect to learn about the evaluation of lymphocytosis including findings that should prompt additional evaluation. They should be able to describe the diagnosis of chronic lymphocytic leukemia, small lymphocytic lymphoma, and monoclonal B-lymphocytosis. They should be able to explain the prognosis of these disease in general terms and understand the implications for health maintenance.

During this second half of the lecture, viewers will learn about prognostic factors important in CLL, the rationale behind the watch and wait approach to therapy, and indications for first treatment.  They will also learn about side effects that are common with the currently used targeted
therapies for this disease.


Type Price
Standard Price $25.00
OSU Affiliated Faculty/Staff $0.00
MedNet 21 Hospital Subscribers $0.00
Accreditation Statement

The Ohio State University Center for Continuing Medical Education (CCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

AMA Credit Designation Statement

The Ohio State University Center for Continuing Medical Education (CCME) designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit is only awarded after successful completion of post-test.
ABIM MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Technical Support
Click Here for technical support documentation.
Downloadable Files
to view PDFs download Adobe Reader
Chronic Lymphocytic Leukemia - 2
Chronic Lymphocytic Leukemia - 4
Chronic Lymphocytic Leukemia - 2 - color
Disclosure Information for Planning Committee Members and Speakers
Listen to Audio Only CME Podcasts
Recommended Reading: iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
You must be logged in to take the Pre-Test
You must be logged in to take the Post-Test.
My CCME Account
CCME Username
Your username is an email address
Forgot Your Password?